• 1. An insight into the origin of room-temperature ferromagnetism in SnO2 and Mn-doped SnO2 quantum dots: an experimental and DFT approach?
  Dhamodaran Manikandan,S. Amirthapandian,I. S. Zhidkov,A. I. Kukharenko,S. O. Cholakh,Ramaswamy Murugan Phys. Chem. Chem. Phys., 2018,20, 6500-6514
• 2. An alumina stabilized graphene oxide wrapped SnO2 hollow sphere LIB anode with improved lithium storage?
  Xiang Liu,Qian Sun,A. B. Djuri?i?,Maohai Xie,Baohu Dai,Jinyao Tang,Charles Surya,Changzhong Liao,Kaimin Shih RSC Adv., 2015,5, 100783-100789
• 3. An intermolecular C–C coupling reaction of iridium complexes?
  Kathrin Kutlescha,Rhett Kempe New J. Chem., 2010,34, 1954-1960
• 4. An air-stable organometallic polymer containing titanafluorene moieties obtained by the Sonogashira–Hagihara cross-coupling polycondensation?
  Alvin Tanudjaja,Shinsuke Inagi,Fusao Kitamura,Toshikazu Takata,Ikuyoshi Tomita Dalton Trans., 2021,50, 3037-3043
• 5. An inter-tangled network of redox-active and conducting polymers as a cathode for ultrafast rechargeable batteries
  Jieun Kim,Han-Saem Park,Tae-Hee Kim,Sung Yeol Kim,Hyun-Kon Song Phys. Chem. Chem. Phys., 2014,16, 5295-5300

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzimidazoles Benzimidazoles
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzimidazoles

Introduction to 1-[(2-chlorophenyl)methyl]-1H-1,3-benzodiazole-2-carbaldehyde (CAS No. 537010-38-1)

1-[(2-chlorophenyl)methyl]-1H-1,3-benzodiazole-2-carbaldehyde is a specialized organic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal research. This compound, identified by its Chemical Abstracts Service (CAS) number 537010-38-1, belongs to the benzodiazole class of heterocyclic compounds, which are widely recognized for their pharmacological properties. The presence of a formyl group at the 2-position and a chlorobenzyl substituent at the 1-position imparts unique reactivity and potential biological activity, making it a subject of interest for synthetic chemists and drug developers.

The structural framework of 1-[(2-chlorophenyl)methyl]-1H-1,3-benzodiazole-2-carbaldehyde consists of a benzodiazole core, which is a bicyclic structure comprising a benzene ring fused to a diazepine ring. The diazepine ring is characterized by two nitrogen atoms, which contribute to its stability and reactivity. The formyl group (CHO) at the 2-position of the benzodiazole ring is a key functional moiety that can participate in various chemical reactions, such as condensation reactions with amino compounds to form Schiff bases or further derivatives. Additionally, the chlorobenzyl group (C?H?ClCH?-) attached to the 1-position introduces electron-withdrawing effects and can influence the electronic properties of the molecule.

Recent advancements in medicinal chemistry have highlighted the importance of benzodiazole derivatives in the development of novel therapeutic agents. The compound 1-[(2-chlorophenyl)methyl]-1H-1,3-benzodiazole-2-carbaldehyde has been studied for its potential applications in several pharmacological contexts. For instance, benzodiazole derivatives are known to interact with gamma-aminobutyric acid (GABA) receptors, which are involved in modulating neuronal excitability. This interaction can lead to effects such as anxiolytic, sedative, and muscle relaxant properties. The specific substitution pattern in 1-[(2-chlorophenyl)methyl]-1H-1,3-benzodiazole-2-carbaldehyde may enhance or modify these effects compared to other benzodiazole analogs.

In addition to their GABAergic activity, benzodiazole derivatives have been explored for their potential role in treating neurological disorders such as epilepsy and Alzheimer's disease. The formyl group in 1-[(2-chlorophenyl)methyl]-1H-1,3-benzodiazole-2-carbaldehyde provides a site for further functionalization, allowing chemists to design molecules with enhanced binding affinity or selectivity for specific targets. For example, modifications at this position could lead to derivatives with improved solubility or metabolic stability, which are crucial factors for drug efficacy and safety.

The synthesis of 1-[(2-chlorophenyl)methyl]-1H-1,3-benzodiazole-2-carbaldehyde involves multi-step organic reactions that require careful optimization to achieve high yields and purity. Common synthetic routes include the Friedel-Crafts alkylation of chlorobenzene followed by condensation with appropriate precursors to form the benzodiazole core. Subsequent functionalization at the 2-position with a formyl group typically involves oxidation or formylation reactions. The use of advanced catalytic systems and green chemistry principles has been increasingly employed to improve the sustainability and efficiency of these synthetic processes.

Recent research has also focused on exploring the pharmacokinetic properties of 1-[(2-chlorophenyl)methyl]-1H-1,3-benzodiazole-2-carbaldehyde and its derivatives. Understanding how a compound is absorbed, distributed, metabolized, and excreted (ADME) is essential for determining its clinical relevance. Studies have shown that structural modifications can significantly impact these processes. For example, optimizing the lipophilicity of the molecule through appropriate substitutions can enhance its ability to cross biological membranes, thereby improving bioavailability.

The potential therapeutic applications of 1-[(2-chlorophenyl)methyl]-1H-1,3-benzodiazole-2-carbaldehyde extend beyond traditional CNS-targeting drugs. Emerging research suggests that benzodiazole derivatives may have roles in anti-inflammatory and antioxidant therapies. The formyl group can participate in redox reactions, potentially making this compound useful in modulating oxidative stress-related diseases. Furthermore, the interaction between benzodiazoles and other biological targets such as enzymes and receptors continues to be an area of active investigation.

In conclusion, 1-[(2-chlorophenyl)methyl] - 1H - 13 -benzodi az ole - 22 - car bal de hyde (CAS No. 537010 -38 - 11) represents a promising scaffold for pharmaceutical development due to its unique structural features and potential biological activities. Ongoing research efforts aim to elucidate its mechanisms of action and explore new therapeutic avenues. As synthetic methodologies continue to evolve，the accessibility and versatility of this compound will likely contribute to its growing significance in medicinal chemistry。

• 3689-76-7(1-(4-chlorophenyl)methyl-2-methyl-1H-1,3-benzodiazole)
• 74298-63-8(Chlormidazole hydrochloride)
• 537010-28-9(1-(1-Naphthylmethyl)-1H-benzimidazole-2-carbaldehyde)
• 537010-34-7(1-(4-chlorophenyl)methyl-1H-1,3-benzodiazole-2-carbaldehyde)
• 537010-29-0(1-(2-Naphthylmethyl)-1H-benzimidazole-2-carbaldehyde)
• 180000-91-3(1-benzyl-1H-1,3-benzodiazole-2-carbaldehyde)
• 54118-67-1(CHLORMIDAZOLE)
• 175713-07-2(1H-Benzimidazole, 1-[(2-chlorophenyl)methyl]-2-(3-methylphenyl)-)
• 341021-39-4({1-(2-chlorophenyl)methyl-1H-1,3-benzodiazol-2-yl}methanol)
• 537010-30-3(1-[(4-methylphenyl)methyl]-1H-1,3-benzodiazole-2-carbaldehyde)